Published January 16, 2015
| Version v1
Journal article
Open
Micro-implant d'acétonide de fluocinolone (ILUVIEN(®)) pour l'œdème maculaire diabétique chronique. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]
Creators
Description
Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a new sustained-release, non biodegradable, injectable, intravitreal micro-implant containing fluocinolone acetonide. The results of the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) studies, conducted to evaluate the efficacy and safety of ILUVIEN(®) in DME, are discussed.
Files
25601517_Postprint.pdf
Files
(1.0 MB)
Name | Size | Download all |
---|---|---|
md5:65c3234027dc490e0ddb00a7db7e390f
|
1.0 MB | Preview Download |
Additional details
Related works
- Is referenced by
- 25601517 (PMID)